TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

Description

This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedule and at the planned dose.

Conditions

Breast Cancer, Stage III Breast Cancer, Breast Cancer Female, Stage I Breast Cancer, Stage II Breast Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedule and at the planned dose.

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients (THRIVE-65)

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Boston

Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Cleveland

Case Western Reserve University/University Hospitals Cleveland, Cleveland, Ohio, United States, 44106

Pittsburgh

University of Pittsburgh, Pittsburgh, Pennsylvania, United States, 15232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Women age \>=65
  • * Diagnosed with stage I-III invasive breast cancer
  • * BMI between 18-50 kg/m2
  • * Scheduled to begin at least 10 weeks of neoadjuvant or adjuvant cytotoxic chemotherapy for curative intent
  • * If enrolled in clinical chemotherapy drug trial, considered eligible if regimen includes an anthracycline or a taxane, unless the trial alters the chemotherapy agents/doses according to patient response (e.g.; I-SPY trials)
  • * Self-reported ability to walk for 6 minutes and/or 2 blocks (with or without assistive device)
  • * Ability to provide written informed consent.
  • * Ability to understand, speak, and read English. This is because many of the study instruments used are not readily available in multiple languages. Additionally, site-based study staff, such as exercise physiologists, are not bilingual and not all sites have access to interpreters.
  • * Following a therapeutic diet for co-morbid disease where the THRIVE-65 diet would be contraindicated as assessed by the RD
  • * Engaging in 2 or more sessions of strength training exercise per week over a period of at least 3 consecutive months over the past year
  • * Engaging in aerobic activity at a level that includes competitive events (e.g., marathon, triathlon, running races) over the past year
  • * Presence of medical conditions or medications that would prohibit participation in an exercise program
  • * Current use of weight-loss medication
  • * Documented history of alcohol or substance abuse within the past 12 months
  • * History of dementia

Ages Eligible for Study

65 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Dana-Farber Cancer Institute,

Kathryn Schmitz (contact), PhD, MPH, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Jennifer Ligibel, MD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Nathan Berger, MD, PRINCIPAL_INVESTIGATOR, Case Western Reserve University/University Hospitals Cleveland

Study Record Dates

2027-02-01